BioSpace News Archive

Qulipta’s label expansion makes it the first oral CGRP receptor antagonist approved for episodic and chronic migraine.

As companies prioritize in-person work, many have begun to do more to incentivize a reluctant workforce to come into the office.

Lilly investigators said they hoped to differentiate their Phase I candidate from the competitive KRAS space by making it the first to gain approval as a first-line treatment.

The leaked data show that Carvykti cuts the risk of disease relapse by 74% versus standard chemotherapy regimens.

When a person notifies their employer that they have a disability, the company must make a good-faith effort to adjust to enable the employee to continue in their job.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 26, 2023 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial results after the market closes on Wednesday, April 26, 2023.

Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery as the standard of care in spine, has announced a leadership change and reorganization, as well as the sale of its Remi® Robotic Navigation System assets to Alphatec Holdings, Inc..

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today presented analytical validation data on its recently launched methylation-based post-diagnosis solution to accelerate cancer research (abstract LB297).

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023.